NCT05709158View on ClinicalTrials.gov

A Study to Learn About the Dangers Linked to Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal Bow Sai Klib)

UnknownOBSERVATIONAL
Enrollment

1,300

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2024

Conditions
Breast Cancer
Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY